Pharmacokinetics of amphotericin B Lipid Complex in Neonates.

A.H. GROLL, G. WÜRTHWEIN, G. HEMPEL, F.C. ADLER-SHOHET, J.M. LIEBERMAN, T.J. WALSH

Author address: 

Univ. Children's Hospital, Münster, Germany, Millers Children's Hospital, Long Beach, CA, National Cancer Institute, Bethesda, MD.

Abstract: 

Background: Little is known about the properties of lipid formulations of amphotericin B in early life. We therefore investigated the disposition of amphotericin B lipid complex (ABLC) in blood, urine and cerebrospinal fluid (CSF) in neonates with invasive candidiasis (IC). Methods: Sparse blood data (153 samples; 1 to 9 per patient, 1 to 154 h after dose) and random urine and CSF samples of 28 neonates (median WT, 1.06 kg; r, 0.48-4.9; median GA: 27 weeks; r, 24-41)with IC were analyzed. Patients received IV ABLC at 2.5 (n=15) or 5 mg/kg (n=13) QD over one or 2 h, for a median of 21 days (r, 4-47). Concentrations in whole blood, urine and CSF were quantified as total amphotericin B by HPLC. Blood concentration data were analyzed using NONMEM and XPOSE. Results: Blood data for time after dose
2003

abstract No: 

M-2058

Full conference title: 

43rd Interscience Conference on Antimicrobial Agents
    • ICAAC 43rd